Filing Details

Accession Number:
0001140361-13-022814
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-24 17:30:02
Reporting Period:
2013-05-22
Filing Date:
2013-05-24
Accepted Time:
2013-05-24 17:30:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1131543 Ambit Biosciences Corp AMBI Pharmaceutical Preparations (2834) 330909648
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1572451 P David Bonita C/O Orbimed Advisors Llc
601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share Acquisiton 2013-05-22 21,100 $6.86 1,464,322 No 4 P Indirect See Footnotes
Common Stock, $0.001 Par Value Per Share Acquisiton 2013-05-22 200 $6.86 13,947 No 4 P Indirect See Footnote
Common Stock, $0.001 Par Value Per Share Acquisiton 2013-05-23 12,380 $6.99 1,476,702 No 4 P Indirect See Footnotes
Common Stock, $0.001 Par Value Per Share Acquisiton 2013-05-23 120 $6.99 14,067 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnote
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnote
Footnotes
  1. The shares were purchased by OrbiMed Private Investments III, LP ("OPI") in multiple transactions and the price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $6.70 to $7.00, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares purchased at each separate price within the ranges set forth in footnote (1) of this Form 4.
  2. The shares were purchased by OrbiMed Associates III, LP ("Associates") in multiple transactions and the price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $6.70 to $7.00, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares purchased at each separate price within the ranges set forth in footnote (2) of this Form 4.
  3. The shares were purchased by OPI in multiple transactions and the price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $6.81 to $7.20, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares purchased at each separate price within the ranges set forth in footnote (3) of this Form 4.
  4. The shares were purchased by Associates in multiple transactions and the price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $6.81 to $7.20, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares purchased at each separate price within the ranges set forth in footnote (4) of this Form 4.
  5. These securities are held of record by OPI and may be deemed to be indirectly beneficially owned by OrbiMed Capital GP III LLC ("Capital"), OrbiMed Advisors LLC ("Advisors") and Samuel D. Isaly ("Isaly"). Capital is the sole general partner of OPI. Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of Capital. By virtue of such relationships, Capital and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI noted above.
  6. Isaly, a natural person, may also be deemed to have voting and investment power with respect to the securities held by OPI noted above in his capacity as the managing member of, and holder of a controlling interest, in Advisors. As a result, each of Capital, Advisors and Isaly may be deemed to have beneficial ownership of the securities held by OPI. The Reporting Person is an employee of Advisors and disclaims beneficial ownership over such securities, except to the extent of his pecuniary interest therein, if any.
  7. These securities are held of record by Associates and may be deemed to be indirectly beneficially owned by Advisors and Isaly. Advisors is the sole general partner of Associates. Isaly is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by Associates noted above. As a result, each of Advisors and Isaly may be deemed to have beneficial ownership of the securities held by Associates. The Reporting Person disclaims beneficial ownership over such securities, except to the extent of his pecuniary interest therein, if any.